Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $25.60 Consensus Target Price from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been given an average rating of “Moderate Buy” by the six analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $11.43.

Several equities analysts have issued reports on ATNM shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. Maxim Group dropped their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday. Stephens began coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price objective for the company. HC Wainwright lowered their target price on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Sanders Morris Harris LLC acquired a new position in shares of Actinium Pharmaceuticals during the first quarter worth about $78,000. Rhumbline Advisers grew its holdings in Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after acquiring an additional 7,525 shares during the period. Virtu Financial LLC raised its position in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after acquiring an additional 62,459 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares in the last quarter. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Trading Up 14.8 %

Shares of NYSE ATNM opened at $2.41 on Friday. The stock has a market cap of $71.78 million, a PE ratio of -1.41 and a beta of 0.20. Actinium Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. Equities analysts forecast that Actinium Pharmaceuticals will post -1.57 EPS for the current year.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.